M&A / Deals Zymeworks cuts deal to buy Theravance for $929m in cash PharmaphorumZymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year.Read full story pharminent June 29, 2026 (Last updated: June 29, 2026) Pharmaphorum Zymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefitNext: UK partners with Eli Lilly on obesity plan Related Stories M&A / Deals Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover pharminent July 16, 2026 M&A / Deals Spero snaps up Innovent immunology drug in strategic pivot pharminent July 14, 2026 M&A / Deals AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5B pharminent July 14, 2026
